RecruitingPHASE1, PHASE2NCT05922930

Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

Studying Adenocarcinoma of ovary

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
Amir Jazaeri, MD
M.D. Anderson Cancer Center
Intervention
TROP2-CAR-NK(drug)
Enrollment
51 enrolled
Eligibility
18 years · All sexes
Timeline
2023 – 2028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05922930 on ClinicalTrials.gov

Other trials for Adenocarcinoma of ovary

Additional recruiting or active studies for the same condition.

See all trials for Adenocarcinoma of ovary →

← Back to all trials